Online Appendix Table 3.

Age-adjusted rates of hypertension, elevated levels of low-density lipoprotein cholesterol, type 2 diabetes, treatment and control among BMI categories, stratified by sex

		% of Participants (95% CI)
		BMI 18.5-<25	BMI 25-<30	BMI ≥30	p-value*
		N=1727	N=1093	N=866
Women	Hypertension
	Prevalence	10.1 (8.6–11.7)	20.8 (18.0–23.8)	34.7 (30.6–39.1)	<0.001
	Treatment	64.0 (52.1–74.8)	67.4 (56.8–76.8)	68.4 (59.1–76.8)	0.15
	Control	37.9 (29.6–46.7)	38.3 (31.1–45.9)	41.0 (34.4–47.9)	0.83
	Elevated LDL–C
	Prevalence	10.4 (8.9–12.0)	22.8 (20.0–25.8)	30.2 (26.4–34.2)	<0.001
	Treatment	39.0 (30.4–48.2)	39.1 (31.7–46.8)	40.7 (33.4–48.3)	0.53
	Control	33.1 (25.3–41.7)	30.3 (23.9–37.2)	31.1 (24.9–37.9)	0.74
	Diabetes
	Prevalence	1.2 (0.8–1.9)	3.5 (2.5–4.8)	12.0 (9.8–14.5)	<0.001
	Treatment	62.5 (24.5–91.5)	62.5 (35.4–84.8)	57.5 (42.2–71.7)	0.51 †
	FPG <126 mg/dL	30.8 (9.1–61.4)	32.3 (16.7–51.4)	12.8 (6.8–21.2)	<0.001
Men		N=731	N=1503	N=881
	Hypertension
	Prevalence	14.8 (12.1–17.9)	24.4 (21.9–27.1)	40.3 (35.9–44.8)	<0.001
	Treatment	50.9 (37.3–64.4)	53.5 (45.7–61.1)	56.9 (48.4–65.0)	0.006
	Control	33.3 (23.4–44.5)	36.1 (30.3–42.1)	36.8-(30.8–43.2)	0.30
	Elevated LDL-C
	Prevalence	18.6 (15.5–22.1)	32.9 (29.9–36.0)	41.1 (36.6–45.8)	<0.001
	Treatment	28.3 (20.2–37.6)	34.9 (30.0–40.0)	38.9 (32.8–45.3)	0.009
	Control	18.5 (12.2–26.2)	23.9 (19.9–28.2)	27.9 (22.8–33.4)	0.009
	Diabetes
	Prevalence	1.7 (0.9–2.9)	4.5 (3.5–5.7)	11.8 ( 9.6–14.3)	<0.001
	Treatment	80.0 (28.4–99.5)	43.8 (26.4–62.3)	52.8 (38.6–66.7)	0.90
	FPG <126 mg/dL	40.0 (12.2–73.8)	14.3 (6.4–26.2)	17.8 ( 10.5–27.3)	0.40

Abbreviations: CI, confidence interval; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; Hb A1c, Hemoglobin A_1c level; FPG, fasting plasma glucose

SI conversion factor: To convert fasting plasma glucose to mmol/L, multiply mg/dL values by 0.0555

^*Global GEE p-value

^†Global ANOVA p-value